Which medications in the drug class Antineoplastics, Tyrosine Kinase Inhibitor are used in the treatment of Waldenstrom Macroglobulinemia?

Updated: May 29, 2020
  • Author: Karen Seiter, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

Antineoplastics, Tyrosine Kinase Inhibitor

Tyrosine kinase enzymes are responsible for activating many proteins by signal transduction cascades, phosphorylation, and other mechanisms. Tyrosine kinase inhibitors block these functions.

Ibrutinib (Imbruvica)

Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor. It forms a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK enzymatic activity. BTK is a signaling molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways. BTK's role in signaling through the B-cell surface receptors results in activation of pathways necessary for B-cell trafficking, chemotaxis, and adhesion. It is indicated for Waldenström macroglobulinemia as either a single-agent or in combination with rituximab.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!